IL-32 has been discovered to activate CD8+ T cells, induce IFN production, and slow down ESCC progression, while simultaneously increasing the immunosuppressive activity of Tregs by promoting Foxp3 expression (112). Here, CD8A is linked to esophageal squamous cell carcinoma.